A new experimental drug called MARY1 reduced kidney damage markers by 52% to 68% and cut kidney scarring by 43% in rats with induced chronic kidney disease, according to research published in Biochemical Pharmacology. The drug works by blocking a receptor called HTR2B and reducing inflammation in kidney tissue. However, this research is still in early animal testing stages and has not been tested in humans.
Researchers have discovered that a new experimental drug called MARY1 may help prevent chronic kidney disease from developing in the first place. According to Gram Research analysis, the drug works by blocking a specific receptor in the body and reducing inflammation and scarring in the kidneys. In a study using rats, MARY1 cut kidney damage markers by more than half and reduced harmful scarring by 43%. While this research is still in early stages and only tested in animals, it suggests a completely new way to treat kidney disease that focuses on prevention rather than managing symptoms after damage occurs.
Key Statistics
A 2026 study in rats found that MARY1, an experimental HTR2B antagonist, reduced kidney injury markers KIM-1 and NGAL by 52% and 68% respectively compared to untreated animals with adenine-induced chronic kidney disease.
Research published in Biochemical Pharmacology showed that MARY1 reduced kidney scarring by 43% and prevented a 69% drop in NAD+, a critical cellular energy molecule, in rats with experimentally induced kidney disease.
According to a 2026 animal study, MARY1 reduced activation of pro-inflammatory pathways ERK and STAT3, cutting NF-κB expression by 64% in rats developing chronic kidney disease from adenine exposure.
The Quick Take
- What they studied: Whether a new drug called MARY1 could prevent chronic kidney disease from developing by blocking a specific protein receptor in the body.
- Who participated: Laboratory rats were divided into groups: some ate normal food, others ate food containing adenine (a chemical that damages kidneys), and some adenine-fed rats also received the experimental drug MARY1 daily for four weeks.
- Key finding: Rats treated with MARY1 had 52% less of one kidney damage marker and 68% less of another compared to untreated rats with kidney damage. The drug also reduced kidney scarring by 43%.
- What it means for you: This research suggests a potential new treatment approach for kidney disease, but it is still in early animal testing stages. Do not expect this drug to be available soon, and anyone with kidney disease should continue following their doctor’s current treatment plan.
The Research Details
Researchers conducted an experiment using laboratory rats to test whether MARY1 could prevent kidney disease. They created kidney disease in rats by feeding them a special diet containing adenine, a chemical that damages the kidneys. Some diseased rats received the experimental drug MARY1 by injection every day, while others received a placebo (fake treatment). All rats were observed for four weeks while the researchers measured various markers of kidney damage and inflammation. This type of study, called a preclinical trial, helps scientists understand whether a potential treatment works before testing it in humans.
Testing new treatments in animals first is crucial because it allows researchers to understand how drugs work at the cellular level and whether they are safe before any human testing occurs. This study design lets scientists measure specific changes in kidney tissue and blood markers that would be difficult or impossible to measure in humans during early research stages. Understanding the exact mechanisms of how MARY1 works helps scientists design better human trials in the future.
This study was published in a peer-reviewed scientific journal, meaning other experts reviewed the research before publication. The researchers used a controlled experimental design with comparison groups, which strengthens the reliability of the findings. However, this is animal research, so results may not translate directly to humans. The study was relatively short (four weeks), so long-term effects remain unknown. The specific number of rats used was not provided in the abstract, which limits our ability to fully assess the study’s statistical power.
What the Results Show
Rats fed the adenine diet developed kidney disease, showing increased levels of two damage markers called KIM-1 and NGAL, along with scarring in the kidney tissue. When MARY1 was given to these diseased rats, it reduced KIM-1 levels by 52% and NGAL levels by 68% compared to untreated diseased rats. The drug also reduced kidney scarring by 43%. Additionally, MARY1 prevented a dangerous drop in a cellular energy molecule called NAD+, which normally decreased by 69% in untreated diseased rats. The drug worked by reducing the activation of two cellular signaling pathways called ERK and STAT3, which are involved in inflammation and tissue damage.
MARY1 reduced the expression of NF-κB, a pro-inflammatory protein that triggers the body’s damaging inflammatory response, by 64%. This suggests the drug’s protective effect works partly by reducing overall inflammation in the kidneys. The drug also appeared to support mitochondrial health, the energy-producing structures inside cells, which is important because mitochondrial dysfunction is a key feature of kidney disease progression.
Previous research showed that MARY1 helped kidneys recover after acute injury from lack of blood flow. This new study extends those findings by showing the drug may also prevent chronic kidney disease from developing in the first place. The focus on blocking the HTR2B receptor as a treatment strategy is relatively novel, representing a different approach than most current kidney disease medications that focus on blood pressure or protein in urine management.
This research was conducted only in rats, so results may not apply to humans. The study lasted only four weeks, which is relatively short for understanding long-term effects. The abstract does not specify how many rats were used, making it difficult to assess whether the sample size was adequate. The adenine-induced kidney disease model, while useful for research, may not perfectly replicate how kidney disease develops in humans. No information was provided about potential side effects of MARY1 or whether it might work differently in humans.
The Bottom Line
This research is too early to recommend MARY1 for any human use. The findings are promising enough to warrant further research and eventual human clinical trials, but many years of additional testing are needed. People with chronic kidney disease should continue following their doctor’s current treatment recommendations, which typically include managing blood pressure, controlling blood sugar if diabetic, and limiting protein and salt intake.
Researchers and pharmaceutical companies developing new kidney disease treatments should pay attention to these findings. People with chronic kidney disease or those at risk for it (such as people with diabetes or high blood pressure) may eventually benefit if this drug proves safe and effective in humans. Healthcare providers treating kidney disease should stay informed about emerging treatment approaches.
If MARY1 moves forward to human testing, it typically takes 5 to 10 years for a new drug to progress from early animal studies to FDA approval. Even if the drug proves effective in humans, it would not be available for several years at minimum.
Frequently Asked Questions
Is there a new treatment for chronic kidney disease?
An experimental drug called MARY1 showed promise in preventing kidney disease in rats by reducing damage markers by 52% to 68% and scarring by 43%. However, it has not been tested in humans yet and remains years away from potential approval.
How does MARY1 protect the kidneys?
MARY1 blocks a protein receptor called HTR2B, which reduces inflammation and supports cellular energy production in kidney tissue. It specifically reduces activation of harmful signaling pathways called ERK and STAT3 that drive kidney damage.
When will MARY1 be available for patients?
MARY1 is still in early research stages and has only been tested in animals. If development continues successfully, human clinical trials would typically begin within 1 to 3 years, with potential FDA approval 5 to 10 years away.
Can I use MARY1 if I have kidney disease now?
MARY1 is not available for human use and should not be used outside of clinical research settings. People with kidney disease should continue their current prescribed treatments and discuss any new experimental options with their nephrologist.
Why test kidney disease drugs in rats first?
Animal testing allows researchers to understand how drugs work at the cellular level and identify potential side effects before any human exposure. This preclinical research is required by regulatory agencies before human clinical trials can begin.
Want to Apply This Research?
- Users with chronic kidney disease can track their kidney function markers (creatinine and eGFR levels from lab tests) monthly or quarterly to monitor disease progression and treatment effectiveness. This data can be compared over time to see if current treatments are slowing kidney damage.
- Users can set reminders to take prescribed kidney disease medications consistently, log dietary sodium and protein intake to stay within recommended limits, and record blood pressure readings daily. These actions directly support kidney health while researchers develop new treatments like MARY1.
- Establish a long-term tracking system that records lab results, blood pressure trends, and medication adherence over months and years. Share this data with healthcare providers during regular appointments to assess whether current treatment strategies are working and whether adjustments are needed.
This article describes early-stage research conducted in laboratory animals. MARY1 is an experimental drug that has not been tested in humans and is not approved by the FDA for any use. The findings from animal studies do not guarantee similar results in humans. Anyone with chronic kidney disease should continue following their doctor’s current treatment plan and should not attempt to obtain or use experimental drugs outside of approved clinical trials. Always consult with a healthcare provider before making any changes to kidney disease treatment or management.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.